Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMED: Sacituzumab Govitecan + Loperamide + G-CSF in Advanced Breast Cancer
NCT05520723Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), luminal breast cancer, sponsored by MEDSIR. Started Feb 2023; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)luminal breast cancer
Beyond the preview
Go deeper on NCT05520723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520723.